Triamcinolone
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Triamcinolone: From Autoimmune and Inflammatory Conditions to Alopecia Mucinosa
One-Sentence Summary
Triamcinolone is a synthetic corticosteroid, originally used for autoimmune and inflammatory conditions such as Crohn disease, adrenocortical insufficiency and eosinophilic pneumonia. The TxGNN model predicts it may be effective for alopecia mucinosa, but no clinical trials and only 2 case reports are available, and neither tests triamcinolone directly. This is a model-based hypothesis, not a clinically validated finding.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Autoimmune disease, Crohn disease and inflammatory bowel disease, adrenocortical insufficiency, acute lymphoblastic leukaemia, eosinophilic pneumonia (from the knowledge graph; no approved-indication text is available from New Zealand licences) |
| Predicted New Indication | Alopecia mucinosa |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L4 |
| New Zealand Market Status | Cancelled only (no currently valid licences) |
| Number of Authorizations | 5 (all cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, triamcinolone is a glucocorticoid that acts on the glucocorticoid receptor (NR3C1) and is used for its anti-inflammatory and immunosuppressive effects. Its efficacy in inflammatory and autoimmune conditions is established, and mechanistically it may be applicable to alopecia mucinosa.
Alopecia mucinosa (follicular mucinosis) often shows a perifollicular inflammatory infiltrate. Intralesional corticosteroids are used empirically for localized disease. However, the supplied literature does not test triamcinolone: one paper is a 1964 case report and the other describes successful treatment with bexarotene gel. The very high TxGNN score reflects a network-based prediction, not clinical validation.
Other predictions in the list are mostly weaker. Folliculitis decalvans (L3) and steroid-sensitive nephrotic syndrome (L4) have somewhat more relevant, though still indirect, literature. Predictions such as telogen effluvium, steroid-resistant nephrotic syndrome and several rare genetic hair disorders are mechanistically doubtful.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23968145 | 2014 | Case report | International Journal of Dermatology | Topical bexarotene 1% gel successfully treated persistent idiopathic follicular mucinosis; this is not a triamcinolone study |
| 14170262 | 1964 | Case report | Hifuka Kiyo. Acta Dermatologica | Case of alopecia mucinosa (Pinkus type, follicular mucinosis); no abstract available |
New Zealand Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 253766 | Kenacort-A 40 | Injection 40 mg/ml, 1 ml ampoule | Not available (cancelled) |
| 282499 | Kenacort-A 10 | Injection 10 mg/ml, 1 ml ampoule | Not available (cancelled) |
| 250066 | Aristocort | Cream 0.02% | Not available (cancelled) |
| 250082 | Aristocort | Ointment 0.02% | Not available (cancelled) |
| 253790 | Kenalog in Orabase | Paste 0.1% | Not available (cancelled) |
Safety Considerations
- Knowledge-graph contraindication signals (from drug-disease network edges, not label text): hypertension, epilepsy, liver disease, gallbladder disease, hyperglycaemia, congestive heart failure, measles, herpes simplex virus keratitis, urea cycle disorders (carbamoyl phosphate synthetase I deficiency, hyperargininemia, citrullinemia), and pituitary hormone deficiency conditions (hypopituitarism, growth hormone deficiency, hypogonadotropic hypogonadism, Kallmann syndrome, Sheehan syndrome).
- Drug Interactions: The interaction search found only the pharmacological target, the glucocorticoid receptor (NR3C1). No drug-drug interactions were identified.
- For alopecia antibody deficiency, the evidence notes that corticosteroids could worsen immunodeficiency-related risks.
Please refer to the package insert for full warnings and contraindications, as this label information was not available for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for alopecia mucinosa has a very high model score but no clinical trials and no triamcinolone-specific literature (L4). All five New Zealand licences are cancelled, so there is no marketed product, and label safety information was not available.
To proceed, the following is needed:
- Medsafe package insert warnings and contraindications (a blocking gap for safety screening)
- Detailed mechanism of action data from DrugBank
- A targeted literature search for intralesional triamcinolone in follicular mucinosis
- A plan for product availability in New Zealand (e.g. unapproved-medicine pathway or re-registration)
- Consideration of better-supported predictions, such as folliculitis decalvans, for a prioritised follow-up
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.